

Human Proteinase 3 (PR3) Immunoassay Kit

Catalogue Number: 31300

For the quantitative determination of human proteinase 3 (PR3) in serum, plasma, plasma samples, cell culture media and other biological samples.

This package insert must be read in its entirety before using this product.
Use only the current version of product data sheet enclosed with the kit.

L8-37, Laboratory Block, The University of Hong Kong,
21, Sassoon Road, Pokfulam, HK
Tel: +852-3917-9743 Fax: +852-2816-2095
E-mail: antibody@hku.hk Website: www.antibody.hku.hk



ImmunoDiagnostics Limited

Product Datasheet

Contents	Page
INTRODUCTION	1
PRINCIPLE OF THE ASSAY	1
INTENDED USE	1
REAGENTS SUPPLIED	2
OTHER MATERIALS REQUIRED, BUT NOT PROVIDED	2
STORAGE	2
PREPARATION OF REAGENTS	3
PREPARATION OF STANDRADS AND SAMPLES	4
ASSAY PROCEDURE	5
CALCULATION	5
TYPICAL STANDARD CURVE	6
REFERENCES	7
SUMMARY OF ASSAY PROCEDURE	8

TABLE OF CONTENTS

Product Datasheet

INTRODUCTION

Proteinase 3 (PR3), also known as myeloblastin, Wegener autoantigen, PRTN3 and NP-4, is one of the hematopoietic serine proteases localized in the primary granules of polymorphonuclear neutrophils (PMNs)^{1,2}. The primary function of PR3 is recognized as to participate in direct intracellular killing of phagocytosed pathogens in phagolysosomes and degradation of extracellular matrix components at inflammatory sites³. PR3 has also been proven to be able to process some pro-inflammatory cytokines, such as IL-1 β , IL-18 and TNF- α , activate mitogen activated protein kinase (MAPK) signaling through proteinase activated receptor-1 (PAR1), and induce endothelial cell apoptosis through NF- κ B signaling pathways^{4,5}. PR3 is identified as the target autoantigen of anti-neutrophil cytoplasmic autoantibodies (ANCA) in Wegener granulomatosis⁶. Increased PR3 levels have been reported in patients with acute myocardial infarction⁷, and in subjects with type 1 diabetes⁸.

PRINCIPLE OF THE ASSAY

This assay is a quantitative sandwich ELISA. The microtiter strips are pre-coated with a polyclonal antibody specific for human PR3. Standards and samples are pipetted into the wells and any human PR3 present is bound by the immobilized antibody. After washing away any unbound substances, a horseradish peroxidase (HRP) labelled polyclonal antibody specific for human PR3 is added to the wells. After wash step to remove any unbound reagents, an HRP substrate solution is added and colour develops in proportion to the amount of human PR3 bound initially. The assay is stopped and the optical density of the wells is determined using a microplate reader. Since the increase in absorbance is directly proportional to the amount of captured human PR3, the unknown sample concentration can be interpolated from a reference curve included in each assay.

INTENDED USE

This human PR3 ELISA kit is designed for quantification of human PR3 in serum, plasma, cell culture media and other biological samples.



REAGENTS SUPPLIED

Each kit is sufficient for one 96-well plate and contains the following components:

1. Micro-titre Strips (96 wells)-Coated with a polyclonal antibody against human PR3, sealed.
2. 10×Wash buffer-40 ml.
3. 5×Assay buffer-30 ml.
4. 100×Detection antibody solution-A polyclonal antibody against human PR3 conjugated to horseradish peroxidase, 0.12 ml.
5. Human PR3 standard-10 ng of recombinant human PR3 in a buffered protein base, lyophilised.
6. Substrate solution- 12 ml, ready for use.
7. Stop solution-12 ml, ready for use.

OTHER MATERIALS REQUIRED, BUT NOT PROVIDED

1. Pipettes and pipette tips.
2. 96-well plate or manual strip washer.
3. Buffer and reagent reservoirs.
4. Paper towels or absorbent paper.
5. Plate reader capable of reading absorbency at 450 nm.
6. Distilled water or deionized water.

STORAGE

The kit should be stored at 2-8°C upon receipt, and all reagents should be equilibrated to room temperature before use. Remove any unused antibody-coated strips from the micro-plate, return them to the foil pouch and re-seal. Once opened, the strips may be stored at 2-8°C for up to one month.



PREPARATION OF REAGENTS

Bring all reagents and materials to room temperature before assay.

1. 1×Assay buffer.

Prepare 1×Assay buffer by mixing the 5×Assay buffer (30 ml) with 120 ml of distilled water or deionized water. If precipitates are observed in the 5× Assay buffer bottle, warm the bottle in a 37°C water bath until the precipitates disappear. The 1×Assay buffer may be stored at 2-8°C for up to one month.

2. 1×Wash buffer.

Prepare 1×Wash buffer by mixing the 10×Wash buffer (40 ml) with 360 ml of distilled water or deionized water. If precipitates are observed in the 10× Wash buffer bottle, warm the bottle in a 37°C water bath until the precipitates disappear. The 1×Wash buffer may be stored at 2-8°C for up to one month.

3. 1×Detection antibody solution.

Spin down the 100×Detection antibody solution briefly and dilute the desired amount of the antibody 1:100 with 1×Assay buffer, 100 µl of the 1×Detection antibody solution is required per well. Prepare only as much 1×Detection antibody solution as needed. Return the 100×Detection antibody solution to 2-8°C immediately after the necessary volume is pipetted.



PREPARATION OF STANDARDS AND SAMPLES

Human PR3 standards: Reconstitute the lyophilised standard with 1 ml of 1×Assay buffer to generate a standard stock solution of 10 ng/ml. Allow the standard to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare serially diluted standards using 1×Assay buffer as follows:

Standard Volume	Volume of 1×Assay buffer	Concentration
10 ng/ml stock	-	10 ng/ml
250 µl of 10 ng/ml	250 µl	5 ng/ml
250 µl of 5 ng/ml	250 µl	2.5 ng/ml
250 µl of 2.5 ng/ml	250 µl	1.25 ng/ml
250 µl of 1.25 ng/ml	250 µl	0.625 ng/ml
250 µl of 0.625 ng/ml	250 µl	0.312 ng/ml
250 µl of 0.312 ng/ml	250 µl	0.156 ng/ml

1x Assay buffer serves as the zero standard (0 ng/ml).

Note: The reconstituted standard stock should be aliquoted and stored at -20°C for up to one month. Avoid repeating freezing/thawing cycles. Please do not store the diluted standard solutions.

Sample preparation

Serum or plasma sample is generally required a 100-fold dilution in 1×Assay buffer. A suggested dilution step is to add 10 µl of sample to 990 µl of 1×Assay buffer. If a sample has a PR3 level greater than the



highest standard, the sample should be diluted further and the assay should be repeated.

ASSAY PROCEDURE

It is recommended that all standards and samples be assayed in duplicate.

1. Add 100 μ l of standard or sample per well, incubate at room temperature for 1 hour.
2. Discard the content and tap the plate on a clean paper towel to remove residual solution in each well. Add 300 μ l of 1 \times Wash buffer to each well and incubate for 1 minute. Discard the 1 \times Wash buffer and tap the plate on a clean paper towel to remove residual wash buffer. Repeat the wash step for a total 3 washes.
3. Add 100 μ l of 1 \times Detection antibody solution to each well, incubate at room temperature for 1 hour.
4. Wash each well 4 times as described in step 2.
5. Add 100 μ l of Substrate solution to each well, incubate at room temperature for 15 minutes. Protect from light.
6. Add 100 μ l of Stop solution to each well, gently tap the plate frame for a few seconds to ensure thorough mixing.
7. Measure absorbance of each well at 450 nm immediately.

CALCULATION

1. Subtract the absorbance of the blank from that of standards and samples.
2. Generate a standard curve by plotting the absorbance obtained (y-axis) against human PR3 concentrations (x-axis). The best fit line can be generated with any curve-fitting software by regression analysis. Any curve of 4-parameter or log-log curve fitting can be used for calculation.
3. Determine human PR3 concentration of samples from standard curve and multiply the value by the dilution factor.




TYPICAL STANDARD CURVE

The following standard curve is provided for demonstration only. A standard curve should be generated for each set of sample assay.

PR3 (ng/ml)	Absorbance (450 nm)	Blanked Absorbance
0	0.056	0
0.156	0.102	0.046
0.312	0.145	0.089
0.625	0.245	0.189
1.25	0.426	0.37
2.5	0.808	0.752
5	1.482	1.426
10	2.603	2.547

Human PR3 standard curve (4-parameter)





REFERENCE

1. Pham, C.T. Neutrophil serine proteases: specific regulators of inflammation. *Nat Rev Immunol* **6**, 541-550 (2006).
2. Nauseef, W.M. & Borregaard, N. Neutrophils at work. *Nature immunology* **15**, 602-611 (2014).
3. Korkmaz, B., Moreau, T. & Gauthier, F. Neutrophil elastase, proteinase 3 and cathepsin G: Physicochemical properties, activity and physiopathological functions. *Biochimie* **90**, 227-242 (2008).
4. Mihara, K., Ramachandran, R., Renaux, B., Saifeddine, M. & Hollenberg, M.D. Neutrophil elastase and proteinase-3 trigger G-protein biased signaling through proteinase activated receptor-1 (PAR1). *J Biol Chem* (2013).
5. Wiedow, O. & Meyer-Hoffert, U. Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. *J Intern Med* **257**, 319-328 (2005).
6. van der Geld, Y.M., Limburg, P.C. & Kallenberg, C.G. Proteinase 3, Wegener's autoantigen: from gene to antigen. *J Leukoc Biol* **69**, 177-190 (2001).
7. Ng, L.L., *et al.* Proteinase 3 and prognosis of patients with acute myocardial infarction. *Clinical science* **120**, 231-238 (2011).
8. Wang, Y., *et al.* Increased Neutrophil Elastase and Proteinase 3 and Augmented NETosis Are Closely Associated with beta-cell Autoimmunity in Patients with Type 1 Diabetes. *Diabetes* (2014).



SUMMARY OF ASSAY PROCEDURE

